Literature DB >> 16552170

Cardiac myocytes Ca2+ and Na+ regulation in normal and failing hearts.

Donald M Bers1, Sanda Despa.   

Abstract

Ca(2+) is a central player in the excitation-contraction coupling of cardiac myocytes, the process that enables the heart to contract and relax. Mishandling of Ca(2+) is a central cause of both contractile dysfunction and arrhythmias in pathophysiological conditions such as heart failure (HF). Upon electrical excitation, Ca(2+) enters the myocytes via voltage-gated Ca(2+) channels and induces further Ca(2+) release from the sarcoplasmic reticulum (SR). This raises the free intracellular Ca(2+) concentration ([Ca(2+)](i)), activating contraction. Relaxation is driven by [Ca(2+)](i) decline, mainly due to re-uptake into the SR via SR Ca(2+)-ATPase and extrusion via the sarcolemmal Na(+)/Ca(2+) exchange, NCX. Intracellular Na(+) concentration ([Na(+)](i)) is a main regulator of NCX, and thus [Na(+)](i) plays an important role in controlling the cytosolic and SR [Ca(2+)]. [Na(+)](i) may have an even more important role in HF because NCX is generally upregulated. There are several pathways for Na(+) entry into the cells, whereas the Na(+)/K(+) pump (NKA) is the main Na(+) extrusion pathway and therefore is essential in maintaining the transmembrane Na(+) gradient. Phospholemman is an important regulator of NKA function (decreasing [Na(+)](i) affinity unless it is phosphorylated). Here we discuss the interplay between Ca(2+) and Na(+) in myocytes from normal and failing hearts.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16552170     DOI: 10.1254/jphs.cpj06001x

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  62 in total

Review 1.  Mitochondrial dynamics in heart disease.

Authors:  Gerald W Dorn
Journal:  Biochim Biophys Acta       Date:  2012-03-16

Review 2.  Recent Developments in Heart Failure.

Authors:  Sujith Dassanayaka; Steven P Jones
Journal:  Circ Res       Date:  2015-09-11       Impact factor: 17.367

3.  Slow [Na]i Changes and Positive Feedback Between Membrane Potential and [Ca]i Underlie Intermittent Early Afterdepolarizations and Arrhythmias.

Authors:  Yuanfang Xie; Zhandi Liao; Eleonora Grandi; Yohannes Shiferaw; Donald M Bers
Journal:  Circ Arrhythm Electrophysiol       Date:  2015-09-25

4.  Dissociation of force decline from calcium decline by preload in isolated rabbit myocardium.

Authors:  Michelle M Monasky; Kenneth D Varian; Jonathan P Davis; Paul M L Janssen
Journal:  Pflugers Arch       Date:  2007-12-04       Impact factor: 3.657

5.  Steady-state coupling of plasma membrane calcium entry to extrusion revealed by novel L-type calcium channel block.

Authors:  William C Lester; Elizabeth A Schroder; Don E Burgess; Doug Yozwiak; Douglas A Andres; Jonathan Satin
Journal:  Cell Calcium       Date:  2008-10       Impact factor: 6.817

6.  Overexpression of the Na+/K+ ATPase α2 but not α1 isoform attenuates pathological cardiac hypertrophy and remodeling.

Authors:  Robert N Correll; Petra Eder; Adam R Burr; Sanda Despa; Jennifer Davis; Donald M Bers; Jeffery D Molkentin
Journal:  Circ Res       Date:  2013-11-11       Impact factor: 17.367

7.  Time-resolved FRET reveals the structural mechanism of SERCA-PLB regulation.

Authors:  Xiaoqiong Dong; David D Thomas
Journal:  Biochem Biophys Res Commun       Date:  2014-05-09       Impact factor: 3.575

8.  Novel pharmacological approaches for antiarrhythmic therapy.

Authors:  Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-01-15       Impact factor: 3.000

9.  Modulation of late sodium current by Ca2+, calmodulin, and CaMKII in normal and failing dog cardiomyocytes: similarities and differences.

Authors:  Victor A Maltsev; Vitaliy Reznikov; Nidas A Undrovinas; Hani N Sabbah; Albertas Undrovinas
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-01-18       Impact factor: 4.733

Review 10.  Molecular aspects of thyroid hormone actions.

Authors:  Sheue-Yann Cheng; Jack L Leonard; Paul J Davis
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.